Announcements Trials
Browse Landscape

Status

Completed 3Withdrawn 1

Sponsor Class

OTHER 104INDUSTRY 4OTHER_GOV 3NIH 3NETWORK 2

Study Type

Interventional 12Observational 4

Sponsor

Cancer Type

Tumor-Agnostic 2Gynecologic 2

Conditions

Ovarian Neoplasms 2Neoplasms 2

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Magnetic Resonance Spectroscopy × Clear all
NCT06390657 2025-05-11

S-C-PATHY

EBG MedAustron GmbH

Withdrawn
Tumor-Agnostic

Neoplasms

NCT05385718 2025-03-03

FasterScan

Ezra AI, Inc.

Completed
694 enrolled
Tumor-Agnostic

Neoplasms

NCT02781272 2023-06-05

EMBER

Angle plc

Completed
200 enrolled
Gynecologic

Ovarian Neoplasms

NCT02785731 2018-11-09

Evaluation of Multiple Biomarkers to Estimate Risk of Ovarian Cancer in Patients With a Pelvic Mass.

Angle plc

Completed
204 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡